<DOC>
	<DOCNO>NCT00868530</DOCNO>
	<brief_summary>This study evaluate safety efficacy on-demand treatment Xyntha Chinese hemophilia A subject .</brief_summary>
	<brief_title>Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Subjects equal 6 year age mild , moderate severe hemophilia A ( FVIII activity : 5 % , 15 % , le 1 % , respectively ) Subjects previous exposure FVIII replacement therapy If human immunodeficiency virus ( HIV ) positive , documented cluster differentiation ( CD4 ) count 200/µL within 6 month study entry Diagnosed bleed disorder addition hemophilia A Current FVIII inhibitor history FVIII inhibitor ( define positive result report laboratory ) Subject history exposure FVIII product ( previously untreated patient [ PUP ] ) Subject currently utilize primary FVIII prophylaxis Subjects anticipate elective surgery may plan occur 6 month follow study entry Treated immunomodulatory therapy within 30 day prior study entry plan use duration study participation Participated another investigational drug device study within 30 day prior study entry plan participation duration study participation Subjects know hypersensitivity hamster protein Significant hepatic renal impairment ( alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] &gt; 5 x upper limit normal [ ULN ] , bilirubin &gt; 2 mg/dL serum creatinine &gt; 1.25 x ULN ) Prothrombin Time &gt; 1.5 x ULN Platelet count &lt; 80,000 / µL Pregnant breastfeed woman Unwilling unable follow term protocol Any condition may compromise subject 's ability comply and/or perform studyrelated activity pose clinical contraindication study participation , opinion Investigator Sponsor</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>On-demand treatment ; Hemostatic Efficacy Assessments ; Factor VIII recovery ; Factor VIII Inhibitor ; Chinese</keyword>
</DOC>